Cara Therapeutics has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or as to the timing of any such agreements or transactions. Cara Therapeutics does not intend to discuss or disclose further developments regarding the exploration of strategic alternatives unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate or required by law. As of March 31, 2024, the Company had approximately $70 million in cash, cash equivalents, and marketable securities.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARA:
- Biotech Alert: Searches spiking for these stocks today
- Cara Therapeutics announces 70% workforce reduction
- Chipotle, McDonald’s initiated: Wall Street’s top analyst calls
- Needham downgrades Cara Therapeutics to Hold on lack of pipeline
- Cara Therapeutics downgraded to Neutral from Buy at H.C. Wainwright